NDLI: Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease

Please wait, while we are loading the content...

Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease

Content Provider	Scilit
Author	Rinne, Juha O. Wesnes, Keith Cummings, Jeffrey L. Hakulinen, Pasi Hallikainen, Merja Hänninen, Jutta Murphy, Michael Riordan, Henry Scheinin, Mika Soininen, Hilkka Rouru, Juha
Copyright Year	2016
Description	Journal: Alzheimer's & Dementia: Translational Research & Clinical Interventions ORM-12741 is a novel selective antagonist of alpha-2C adrenoceptors. This trial evaluated the safety and efficacy of ORM-12741 in patients with Alzheimer's disease (AD). A randomized, double-blind, placebo-controlled, exploratory phase 2a trial was conducted in 100 subjects with AD and neuropsychiatric symptoms. Participants were randomized to receive one of two flexible doses of ORM-12741 (30–60 mg or 100–200 mg) or placebo b.i.d. for 12 weeks in addition to standard therapy with cholinesterase inhibitors. Efficacy was assessed primarily with the Cognitive Drug Research (CDR) computerized assessment system and secondarily with the Neuropsychiatric Inventory (NPI). A statistically significant treatment effect was seen in one of the four primary CDR system end points, Quality of Episodic Memory (P = .030; not adjusted for multiple comparisons), favoring ORM-12741 over placebo. NPI caregiver distress scores also favored ORM-12741 (P = .034). ORM-12741 was well tolerated. This is the first clinical trial providing evidence on an acceptable safety profile for ORM-12741 in patients with AD and neuropsychiatric symptoms. In addition, the trial provided hints of potential therapeutic benefit, primarily on episodic memory, in this patient population.
Related Links	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651366/pdf
Ending Page	9
Page Count	9
Starting Page	1
ISSN	23528737
e-ISSN	23528737
DOI	10.1016/j.trci.2016.11.004
Journal	Alzheimer's & Dementia: Translational Research & Clinical Interventions
Issue Number	1
Volume Number	3
Language	English
Publisher	Wiley-Blackwell
Publisher Date	2016-12-08
Access Restriction	Open
Subject Keyword	Journal: Alzheimer's & Dementia: Translational Research & Clinical Interventions Clinical Psychology Alzheimer's Disease Alpha-2c Adrenoceptor Antagonist Randomized Trials Behavioral and Psychological Symptoms of Dementia Neuropsychiatric Symptoms
Content Type	Text
Resource Type	Article
Subject	Neurology (clinical) Psychiatry and Mental Health

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in